A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer.
Adenocarcinoma
/ diagnosis
Adult
Aged
Aged, 80 and over
Antigens, Tumor-Associated, Carbohydrate
/ blood
Biomarkers, Tumor
/ blood
Blood Chemical Analysis
/ methods
Carcinoma, Pancreatic Ductal
/ diagnosis
Cell-Free Nucleic Acids
/ blood
Diagnosis, Differential
Diagnostic Tests, Routine
/ methods
Early Diagnosis
Female
Humans
Male
Middle Aged
Thrombospondins
/ blood
Young Adult
CA19-9
circulating tumor DNA
liquid biopsy
pancreatic cancer
thrombospondin-2
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
08
2018
accepted:
10
01
2019
entrez:
15
3
2019
pubmed:
15
3
2019
medline:
1
2
2020
Statut:
epublish
Résumé
The most frequent malignancy of the pancreas is the pancreatic ductal adenocarcinoma (PDAC). Despite many efforts PDAC has still a dismal prognosis. Biomarkers for early disease stage diagnosis as a prerequisite for a potentially curative treatment are still missing. Novel blood-based markers may help to overcome this limitation. Methods: Prior to surgery plasma levels of thrombospondin-2 (THBS2), which was recently published as a novel biomarker, and CA19-9 from 52 patients with histologically proven PDAC were determined, circulating cell-free (cfDNA) was quantified. 15 patients with side-branch IPMNs without worrisome features and 32 patients with chronic pancreatitis served for comparison. Logit (logistic regression) models were used to test the performance of single biomarkers and biomarker combinations. Results: CA19-9 and THBS2 alone showed comparable c-statistics of 0.80 and 0.73, respectively, improving to 0.87 when combining these two markers. The c-statistic was further increased to 0.94 when combining CA19-9 and THBS2 with cfDNA quantification. This marker combination performed best for all PDAC stages but also for PDACs grouped by stage. The greatest improvement over CA19-9 was seen in the group of stage I PDAC, from 0.69 to 0.90 for the three marker combination.
Identifiants
pubmed: 30867830
doi: 10.7150/thno.29247
pii: thnov09p1280
pmc: PMC6401492
doi:
Substances chimiques
Antigens, Tumor-Associated, Carbohydrate
0
Biomarkers, Tumor
0
Cell-Free Nucleic Acids
0
Thrombospondins
0
thrombospondin 2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1280-1287Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Oncotarget. 2016 Jul 5;7(27):41575-41583
pubmed: 27223429
Nat Med. 2014 Oct;20(10):1193-1198
pubmed: 25261994
J Clin Oncol. 2014 Feb 20;32(6):579-86
pubmed: 24449238
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
Nat Rev Dis Primers. 2016 Apr 21;2:16022
pubmed: 27158978
J Interv Gastroenterol. 2012 Jan-Mar;2(1):31-36
pubmed: 22586548
Diabetes Metab. 1998 Jun;24(3):241-3
pubmed: 9690057
Lancet. 2011 Aug 13;378(9791):607-20
pubmed: 21620466
Ann Surg Oncol. 2013 Jul;20(7):2188-96
pubmed: 23247983
Clin Cancer Res. 2017 Jan 1;23(1):116-123
pubmed: 27993964
Eur J Surg Oncol. 2007 Apr;33(3):266-70
pubmed: 17097848
J Clin Oncol. 2006 Nov 20;24(33):5313-27
pubmed: 17060676
JAMA. 2013 Oct 9;310(14):1473-81
pubmed: 24104372
Sci Transl Med. 2017 Jul 12;9(398):
pubmed: 28701476
Cell Rep. 2013 Jun 27;3(6):2088-99
pubmed: 23791528
Gastrointest Endosc. 1997 Mar;45(3):243-50
pubmed: 9087830
Pancreas. 2009 Jul;38(5):534-41
pubmed: 19295453
HPB (Oxford). 2004;6(3):144-53
pubmed: 18333068
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10202-10207
pubmed: 28874546
Z Gastroenterol. 2013 Dec;51(12):1395-440
pubmed: 24338757
PLoS One. 2017 Mar 22;12(3):e0174308
pubmed: 28328955
J Surg Oncol. 1985 May;29(1):15-21
pubmed: 3857396
Nature. 2013 May 2;497(7447):108-12
pubmed: 23563269
J Clin Oncol. 2017 Feb 10;35(5):515-522
pubmed: 27621388
Clin Cancer Res. 2018 Aug 1;24(15):3539-3549
pubmed: 29691297
Clin Epigenetics. 2015 Oct 07;7:106
pubmed: 26451166
Science. 2018 Feb 23;359(6378):926-930
pubmed: 29348365
Nature. 2012 Jun 28;486(7404):537-40
pubmed: 22722843
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Gastroenterology. 2016 Aug;151(2):267-70
pubmed: 27343369
Oncotarget. 2017 Dec 16;9(2):2076-2085
pubmed: 29416754
Nat Commun. 2015 Apr 09;6:6744
pubmed: 25855536
ACS Nano. 2017 Nov 28;11(11):11182-11193
pubmed: 29019651
JAMA Oncol. 2018 Jul 1;4(7):963-969
pubmed: 29800971
Ann Oncol. 2015 Sep;26 Suppl 5:v56-68
pubmed: 26314780
J Biochem. 2008 Jun;143(6):725-9
pubmed: 18218651
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Endoscopy. 1997 Nov;29(9):854-8
pubmed: 9476770
J Gastrointest Oncol. 2012 Jun;3(2):105-19
pubmed: 22811878
J Proteome Res. 2009 Mar;8(3):1565-76
pubmed: 19199705
Endosc Ultrasound. 2016 Jul-Aug;5(4):258-62
pubmed: 27503159
Nanomedicine. 2018 Aug;14(6):1823-1832
pubmed: 29782949
EMBO J. 2001 Jun 1;20(11):2631-40
pubmed: 11387198
Nature. 2015 Jul 9;523(7559):177-82
pubmed: 26106858
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):413-423
pubmed: 29625841
J Natl Compr Canc Netw. 2014 Aug;12(8):1083-93
pubmed: 25099441
JAMA. 2014 Jan 22-29;311(4):392-404
pubmed: 24449318
Nat Med. 2008 Sep;14(9):985-90
pubmed: 18670422
Ann Oncol. 2010 Mar;21(3):441-7
pubmed: 19690057